Tepotinib Safety in MET Exon 14+ NSCLC Treatment
Summary of Tepotinib Side Effects & Quality of Life Findings from the VISION Trial:
Here’s a breakdown of the data provided regarding tepotinib’s side effects adn impact on patient quality of life, based on the VISION trial:
1. Common Treatment-Related Adverse Events (TRAEs):
Very Common (≥10%):
Peripheral edema (37.2%)
Decreased appetite (11.5%)
Elevated aspartate aminotransferase levels (11.2%)
Increased amylase levels (10.5%)
Dose Reductions: 37.4% of patients required at least one dose reduction, most commonly due to peripheral edema (15.3%).
Treatment Interruptions/Discontinuations: Peripheral edema was the most common reason for interrupting (18.8%) and discontinuing (6.1%) treatment. Other reasons included generalized edema, pleural effusion, increased creatinine levels, and, less frequently, interstitial lung disease and pneumonitis.
2. Impact on Health-Related Quality of Life (HRQOL):
Overall Stability: HRQOL scores (EORTC QLQ-C30 and EQ-5D-5L) remained stable throughout the trial (up to 228 weeks).
Specific Symptom Advancement:
Cough: Improved (mean change from baseline -6.1)
Chest Pain: Improved (mean change from baseline -2.3)
Dyspnea (Shortness of Breath): Remained stable.
Time to Deterioration: Median time to deterioration of symptom scores was relatively long for cough (36.5 months) and chest pain (30.4 months), but shorter for dyspnea (5.5 months).
Patient Reported Outcomes: Patients reported that their health and quality of life remained stable while receiving tepotinib.
3. VISION Trial Design (Briefly):
Type: Single-arm study
Patients: Advanced NSCLC with MET exon 14 skipping alterations.
Dose: 500mg tepotinib orally once daily.
eligibility: Age ≥18, confirmed NSCLC with MET alterations, measurable disease, good performance status (ECOG 0 or 1). Prior immunotherapy allowed.
Exclusion: EGFR mutations or ALK* rearrangements.
in essence, the data suggests that while tepotinib has some common side effects (particularly edema), it doesn’t considerably worsen patients’ quality of life and may even improve certain symptoms like cough and chest pain.